• EnClear Spins out of QurAlis americanpharmaceuticalreview
    December 29, 2018
    EnClear Therapies has spun-out from QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases. EnClear’s mission is to halt the progression of ....
  • QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria Venture americanpharmaceuticalreview
    April 09, 2018
    QurAlis announced the addition of biotech investors MP Healthcare Venture Management (MPH), Amgen Ventures, and Alexandria Venture Investments, who have joined to cure Amyotrophic Lateral Sclerosis (ALS)
PharmaSources Customer Service